Published in Proc Natl Acad Sci U S A on October 01, 1996
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J (2000) 4.85
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A (2000) 4.41
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev (1998) 4.29
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A (1999) 3.43
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol (1998) 3.30
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev (1999) 3.17
Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res (2006) 3.04
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol (1997) 2.76
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J (2006) 2.41
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell (2008) 2.38
Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A (1998) 2.20
Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol Cell Biol (2000) 2.12
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer (2011) 2.06
HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest (2003) 1.99
Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal (2010) 1.85
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell (2003) 1.85
Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol Cell Biol (2003) 1.83
Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc Natl Acad Sci U S A (1999) 1.78
A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci U S A (1998) 1.77
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A (1998) 1.74
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol (1999) 1.62
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol (2007) 1.62
The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ (2008) 1.61
Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.59
Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cell Mol Life Sci (2010) 1.58
Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol (2010) 1.55
Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer (2006) 1.54
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. Eur Urol (2008) 1.48
Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci U S A (1999) 1.42
von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays. Mol Cell Biol (2003) 1.37
The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol (2005) 1.34
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol (1999) 1.30
Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol (1997) 1.29
Erythropoietin. Cold Spring Harb Perspect Med (2013) 1.28
Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr (1997) 1.28
Neurologic manifestations of von Hippel-Lindau disease. JAMA (2008) 1.26
pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol (2006) 1.18
Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol (2002) 1.16
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol (2006) 1.16
Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One (2011) 1.11
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer (2011) 1.07
Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids Res (2005) 1.07
Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol (1998) 1.06
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia (2009) 1.05
The Role of Elongin BC-Containing Ubiquitin Ligases. Front Oncol (2012) 1.04
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int (2009) 1.03
Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol (2000) 1.02
Binding of elongin A or a von Hippel-Lindau peptide stabilizes the structure of yeast elongin C. Proc Natl Acad Sci U S A (1999) 1.02
Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest (2008) 1.00
Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol (1999) 0.98
Identification of Jade1, a gene encoding a PHD zinc finger protein, in a gene trap mutagenesis screen for genes involved in anteroposterior axis development. Mol Cell Biol (2003) 0.98
The von Hippel-Lindau gene: turning discovery into therapy. Cancer (2008) 0.97
Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA. Mol Cancer Res (2011) 0.97
Highly conserved RNA sequences that are sensors of environmental stress. Mol Cell Biol (1998) 0.95
The molecular basis of von Hippel-Lindau disease. Mol Med (1997) 0.95
Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma. Trans Am Ophthalmol Soc (2004) 0.94
Ubiquitin pathway in VHL cancer syndrome. Neoplasia (2006) 0.94
Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. Invest Ophthalmol Vis Sci (2010) 0.94
RSUME inhibits VHL and regulates its tumor suppressor function. Oncogene (2014) 0.94
4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. J Med Chem (2010) 0.94
Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol (2006) 0.94
Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia. J Biol Chem (2009) 0.93
Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent) (2007) 0.92
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series. World J Urol (2012) 0.88
Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br J Cancer (2000) 0.87
RBMS3 at 3p24 inhibits nasopharyngeal carcinoma development via inhibiting cell proliferation, angiogenesis, and inducing apoptosis. PLoS One (2012) 0.86
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene (2011) 0.85
Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis. J Thyroid Res (2011) 0.85
Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opin Drug Discov (2008) 0.85
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar Drugs (2009) 0.85
The association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: a systematic review and meta-analysis. PLoS One (2015) 0.83
Neural driven angiogenesis by overexpression of nerve growth factor. Histochem Cell Biol (2005) 0.83
The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions. Cell Div (2016) 0.82
Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter. J Med Genet (2002) 0.82
Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes. Br J Cancer (1998) 0.82
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue. Virchows Arch (2010) 0.80
ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. PLoS One (2012) 0.80
Role of the ubiquitin proteasome system in renal cell carcinoma. BMC Biochem (2007) 0.80
Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function. J Cell Sci (2011) 0.79
Roles of main pro- and anti-angiogenic factors in tumor angiogenesis. World J Gastroenterol (2004) 0.79
Hallmarks of cancer and AU-rich elements. Wiley Interdiscip Rev RNA (2016) 0.78
Signaling hypoxia by hypoxia-inducible factor protein hydroxylases: a historical overview and future perspectives. Hypoxia (Auckl) (2014) 0.78
Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists. Can Urol Assoc J (2007) 0.78
Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma. J Kidney Cancer VHL (2015) 0.78
ARNT2 Regulates Tumoral Growth in Oral Squamous Cell Carcinoma. J Cancer (2016) 0.77
Lack of a phenotype in transgenic mice aberrantly expressing COL2A1 mRNA because of highly selective post-transcriptional down-regulation. Biochem J (2000) 0.76
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. Biologics (2010) 0.75
Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res (2016) 0.75
SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells. Bioorg Med Chem (2011) 0.75
Intramedullary Spinal Cord Tumors: Part I-Epidemiology, Pathophysiology, and Diagnosis. Global Spine J (2015) 0.75
Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome. PLoS One (2014) 0.75
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 18.26
Angiogenic factors. Science (1987) 15.22
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Angiogenesis. J Biol Chem (1992) 11.29
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 9.73
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature (1986) 7.19
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem (1995) 5.20
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (1995) 4.93
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell (1992) 4.90
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med (1995) 4.71
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Antioncogenes and human cancer. Proc Natl Acad Sci U S A (1993) 4.09
Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem (1996) 3.80
Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem (1995) 3.69
Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem (1994) 3.68
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res (1994) 3.62
Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science (1995) 3.53
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol (1993) 2.85
Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet (1994) 2.65
Multiple determinants of eukaryotic mRNA stability. New Biol (1989) 2.52
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA (1995) 2.43
Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest (1993) 2.42
Regulation of human histone gene expression during the HeLa cell cycle requires protein synthesis. Mol Cell Biol (1984) 2.38
Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett (1995) 2.31
Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res (1995) 2.23
Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res (1994) 2.13
Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem (1992) 2.12
Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol (1993) 1.93
Translation and the stability of mRNAs encoding the transferrin receptor and c-fos. Proc Natl Acad Sci U S A (1991) 1.93
Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet (1994) 1.80
Common mechanisms for the control of eukaryotic transcriptional elongation. Bioessays (1993) 1.68
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A (1996) 1.66
Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res (1994) 1.58
Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst (1989) 1.56
Dissection of transcription factor TFIIF functional domains required for initiation and elongation. Proc Natl Acad Sci U S A (1995) 1.32
VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res (1995) 1.17
Regulation of human tissue factor expression by mRNA turnover. J Biol Chem (1993) 1.15
Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res (1995) 1.10
Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes Cancer (1995) 1.01
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A (2002) 13.83
Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell (1989) 13.41
Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin A suggests an ER recycling pathway. Cell (1990) 9.19
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science (1999) 7.51
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
The mammalian gene collection. Science (1999) 7.19
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J (1996) 6.36
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell (1991) 6.30
Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein. Nature (1992) 6.11
Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev (1996) 6.01
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. Proc Natl Acad Sci U S A (1982) 5.74
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 5.47
Association of the fyn protein-tyrosine kinase with the T-cell antigen receptor. Proc Natl Acad Sci U S A (1990) 5.35
Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun (2003) 5.11
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
SOX9 directly regulates the type-II collagen gene. Nat Genet (1997) 4.88
Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science (1988) 4.86
A systematic, high-resolution linkage of the cytogenetic and physical maps of the human genome. Nat Genet (2000) 4.78
Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc Natl Acad Sci U S A (1983) 4.68
A permease-oxidase complex involved in high-affinity iron uptake in yeast. Science (1996) 4.60
Elucidating the pathophysiology of syringomyelia. J Neurosurg (1999) 4.43
Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins. Cell (1988) 4.42
A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell (1992) 4.39
Binding of a cytosolic protein to the iron-responsive element of human ferritin messenger RNA. Science (1988) 4.35
Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science (1986) 4.30
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
ADP-ribosylation factor, a small GTP-binding protein, is required for binding of the coatomer protein beta-COP to Golgi membranes. Proc Natl Acad Sci U S A (1992) 4.22
Identification of the components of the murine T cell antigen receptor complex. Cell (1985) 4.20
Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science (1987) 4.20
Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae. Cell (1991) 4.17
Dissociation of a 110-kD peripheral membrane protein from the Golgi apparatus is an early event in brefeldin A action. J Cell Biol (1990) 3.90
Molecular characterization of a copper transport protein in S. cerevisiae: an unexpected role for copper in iron transport. Cell (1994) 3.88
Overexpression of wild-type and mutant ARF1 and ARF6: distinct perturbations of nonoverlapping membrane compartments. J Cell Biol (1995) 3.82
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem (1983) 3.65
Failure to synthesize the T cell CD3-zeta chain: structure and function of a partial T cell receptor complex. Cell (1988) 3.59
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Oxidation-reduction and the molecular mechanism of a regulatory RNA-protein interaction. Science (1989) 3.54
Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A (1999) 3.43
Binding of ARF and beta-COP to Golgi membranes: possible regulation by a trimeric G protein. Science (1991) 3.33
Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature (1999) 3.32
Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell (1986) 3.30
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
Membrane protein association by potential intramembrane charge pairs. Nature (1991) 3.27
Lipid domains in membranes. Evidence derived from structural perturbations induced by free fatty acids and lifetime heterogeneity analysis. J Biol Chem (1980) 3.20
Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia (2005) 3.13
Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation. Nature (1989) 3.02
The cancer genome anatomy project: building an annotated gene index. Trends Genet (2000) 3.02
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology (1996) 2.90
A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. Proc Natl Acad Sci U S A (1987) 2.89
Ferric reductase of Saccharomyces cerevisiae: molecular characterization, role in iron uptake, and transcriptional control by iron. Proc Natl Acad Sci U S A (1992) 2.87
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86
Genetic evidence that ferric reductase is required for iron uptake in Saccharomyces cerevisiae. Mol Cell Biol (1990) 2.83
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A (1999) 2.81
A cytosolic protein binds to structural elements within the iron regulatory region of the transferrin receptor mRNA. Proc Natl Acad Sci U S A (1989) 2.81
Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther (2001) 2.79
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med (1997) 2.76
AFT1: a mediator of iron regulated transcriptional control in Saccharomyces cerevisiae. EMBO J (1995) 2.76
In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res (1993) 2.74
Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3' UTR and does not involve poly(A) tail shortening. EMBO J (1994) 2.70
A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol (2000) 2.70
Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells. J Virol (2001) 2.69
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon. Science (1992) 2.67
Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: intrinsic sensitivity and the role of subunit assembly. J Cell Biol (1989) 2.65
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Iron-regulated DNA binding by the AFT1 protein controls the iron regulon in yeast. EMBO J (1996) 2.62
The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature (1999) 2.61
New opportunities for uncovering the molecular basis of cancer. Nat Genet (1997) 2.61
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol (1995) 2.59
Building a multichain receptor: synthesis, degradation, and assembly of the T-cell antigen receptor. Proc Natl Acad Sci U S A (1987) 2.58
Molecular cloning of the zeta chain of the T cell antigen receptor. Science (1988) 2.58
Conservation. Reconsidering the consequences of selective fisheries. Science (2012) 2.57
The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. J Biol Chem (1994) 2.57
Iron regulation of transferrin receptor mRNA levels requires iron-responsive elements and a rapid turnover determinant in the 3' untranslated region of the mRNA. EMBO J (1989) 2.54
Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes. Proc Natl Acad Sci U S A (1982) 2.54
High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther (2009) 2.54
The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev (1999) 2.52
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
The Menkes/Wilson disease gene homologue in yeast provides copper to a ceruloplasmin-like oxidase required for iron uptake. Proc Natl Acad Sci U S A (1995) 2.50
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50